Corcept Therapeutics company profile

CORT · NASDAQ · USD

Compare Corcept Therapeutics
$70.07Change from previous close: +1.23%Absolute change: +$0.85

Close · November 17, 2026

Company profile

Corcept Therapeutics has 730 employees and is headquartered in Redwood City, United States.

With 730 employees, Corcept Therapeutics develops medicines that modulate cortisol activity for conditions linked to excess cortisol. Its marketed product, Korlym, is prescribed in the United States to control blood sugar in adults with Cushing's syndrome who have type 2 diabetes or impaired glucose tolerance and who either did not respond to surgery or cannot undergo it. The pipeline includes relacorilant for hypercortisolism, miricorilant, which is in a Phase 1b study for metabolic dysfunction-associated steatohepatitis, and several cortisol modulators, among them dazucorilant, for Lou Gehrig's disease.

In the fiscal year ended December 2025, revenue reached USD 761.4 million, up 12.8% from the prior year, and net income came to USD 99.7 million. The company was founded in 1998 and is headquartered in Redwood City, California.

Company facts

Industry
Biotechnology
Headquarters
101 Redwood Shores Parkway, 94065, Redwood City
Employees
730
Chief executive
Joseph Belanoff
Founded
1998
Fiscal year
January - December
Listing
CORT · NASDAQ
Currency
USD
ISIN
US2183521028

Corcept Therapeutics and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Corcept TherapeuticsCORTUnited States$9.36B7300.8%190.2
Madrigal PharmaceuticalsMDGLUnited States$9.93B915-10.7%—
BioMarin PharmaceuticalBMRNUnited States$11.09B3,22116.3%146.8
Summit TherapeuticsSMMTUnited States$11.32B2650.0%—
Bio-TechneTECHUnited States$11.43B3,00021.7%66.8
Twist BioscienceTWSTUnited States$7.4B979-28.8%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Corcept Therapeutics with its competitors